(Q36488803)

14 August 2017

1 reference

title

Blood safety and the choice of anti-hemophilic factor concentrate. (English)

1 reference

14 August 2017

0 references

Leonard A Valentino

1

1 reference

14 August 2017

Veeral M Oza

series ordinal

2

1 reference

14 August 2017

publication date

1 September 2006

1 reference

14 August 2017

published in

Pediatric Blood Cancer

1 reference

14 August 2017

volume

47

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

245-254

1 reference

Treatment strategies in children with hemophilia

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPBC.20895

Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPBC.20895

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

SEN virus infection and its relationship to transfusion-associated hepatitis

1 reference

12 December 2020

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group

1 reference

12 December 2020

Deaths from variant Creutzfeldt-Jakob disease in the UK.

1 reference

12 December 2020

Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979.

1 reference

12 December 2020

A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.

1 reference

12 December 2020

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

1 reference

12 December 2020

Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3.

1 reference

12 December 2020

Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans

1 reference

12 December 2020

1 reference

12 December 2020

Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation

1 reference

12 December 2020

Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products

1 reference

12 December 2020

The public health impact of prion diseases

1 reference

12 December 2020

Variant CJD transmission through blood: risks to predictors and "predictees"

1 reference

12 December 2020

The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy

1 reference

12 December 2020

Horizontal prion transmission in mule deer

1 reference

12 December 2020

A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation

1 reference

12 December 2020

Inactivation of prions by physical and chemical means

1 reference

12 December 2020

The spectrum of safety: a review of the safety of current hemophilia products

1 reference

12 December 2020

Treatment of hemophilia: recombinant factors only? Yes.

1 reference

12 December 2020

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

1 reference

12 December 2020

CDC/hemophilia study targets blood safety and joint disease. Centers for Disease Control and Prevention

1 reference

12 December 2020

Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs).

1 reference

12 December 2020

Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia

1 reference

12 December 2020

Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.

1 reference

12 December 2020

Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients

1 reference

12 December 2020

Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.

1 reference

12 December 2020

Impacts and concerns for vCJD in blood transfusion: current status

1 reference

12 December 2020

Insights into SEN virus prevalence, transmission, and treatment in community-based persons and patients with liver disease referred to a liver disease unit

1 reference

12 December 2020

Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent

1 reference

12 December 2020

Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group

1 reference

12 December 2020

Inhibitors in congenital coagulation disorders

1 reference

12 December 2020

A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins

1 reference

12 December 2020

Human parvovirus B19.

1 reference

12 December 2020

Advances in chronic viral hepatitis

1 reference

12 December 2020

Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2

1 reference

12 December 2020

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

1 reference

12 December 2020

Transmissible Spongiform Encephalopathies. Managing risk in mammalian organs, cells and sera. 15-16 March 1999, San Diego, CA, USA.

1 reference

12 December 2020

Safety issues affecting hemophilia products.

1 reference

12 December 2020

Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma.

1 reference

12 December 2020

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products

1 reference

12 December 2020

The incidence of viremia and the heterogeneity of hepatitis C virus genotypes among blood donors, hemophiliacs and patients with chronic liver disease

1 reference

12 December 2020

Transfusion-transmitted virus is not present in factor IX concentrates commonly used to treat haemophilia B.

1 reference

12 December 2020

From the Centers for Disease Control and Prevention. Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002

1 reference

12 December 2020

Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia

1 reference

12 December 2020

Haemophilia 2002: emerging risks of treatment

1 reference

12 December 2020

Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans

1 reference

12 December 2020

AIDS — The First 20 Years

1 reference

12 December 2020

Transmission of BSE by blood transfusion in sheep

1 reference

12 December 2020

The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary

1 reference

12 December 2020

T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.

1 reference

12 December 2020

Clinical trials of the recombinant factor VIII product, Kogenate

1 reference

12 December 2020

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group

1 reference

12 December 2020

West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data

1 reference

12 December 2020

Blood infectivity in transmissible spongiform encephalopathies

1 reference

12 December 2020

Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.

1 reference

12 December 2020

GB virus C/Hepatitis G virus infection is frequent in American children and young adults

1 reference

12 December 2020

Hepatitis B vaccination in children with thalassemia, hemophilia and cancer

1 reference

12 December 2020

GB virus-C/hepatitis G virus.

1 reference

12 December 2020

Update: severe acute respiratory syndrome--United States, June 4, 2003.

1 reference

12 December 2020

Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.

1 reference

12 December 2020

Emerging, re-emerging and submerging infectious threats to the blood supply

1 reference

12 December 2020

A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology

1 reference

12 December 2020

Vaccination against hepatitis A virus in French hemophilic children

1 reference

12 December 2020

Safety of therapeutic products used for hemophilia patients.

1 reference

12 December 2020

[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia]

1 reference

12 December 2020

Clinical perspectives of emerging pathogens in bleeding disorders.

1 reference

12 December 2020

Hepatitis B virus infection--natural history and clinical consequences

1 reference

12 December 2020

TT virus contaminates first-generation recombinant factor VIII concentrates

1 reference

12 December 2020

Effects on instruments of the World Health Organization--recommended protocols for decontamination after possible exposure to transmissible spongiform encephalopathy-contaminated tissue.

1 reference

12 December 2020

Identification of two flavivirus-like genomes in the GB hepatitis agent

1 reference

12 December 2020

A new variant of Creutzfeldt-Jakob disease in the UK.

1 reference

12 December 2020

Accelerated schedule of hepatitis B vaccination in patients with hemophilia.

1 reference

12 December 2020

Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience

1 reference

12 December 2020

Blood products for hemophilia: past, present and future

1 reference

12 December 2020

Summary of clinical experience with recombinant factor VIII products--Recombinate

1 reference

12 December 2020

Circular double-stranded forms of TT virus DNA in the liver

1 reference

12 December 2020

Emerging viral diseases and infectious disease risks

1 reference

12 December 2020

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

12 December 2020

Update: influenza activity--United States and worldwide, 2002-03 season, and composition of the 2003-04 influenza vaccine.

1 reference

12 December 2020

Treatment of hemophilia: recombinant factors only? No.

1 reference

12 December 2020

Leads from the MMWR. Safety of therapeutic products used for hemophilia patients

1 reference

12 December 2020

Identifiers

DOI

10.1002/PBC.20895

1 reference

14 August 2017

0 references

1 reference